This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif.,
Sept. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on
October 2 at the Le Parker Meridien in
New York City. KaloBios President and Chief Executive Officer,
David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
Company Presentation: When:
Wednesday, October 2, 2013,
10:30 AM EDT Where: Le Parker Meridien,
New York City, NY
Webcast: To access the live and archived audio webcast of this presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab:
A replay of the webcast will be available one hour after the conclusion of the live event.
About KaloBios KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at
Contact:Jeffrey H. Cooper Chief Financial Officer KaloBios Pharmaceuticals, Inc. (650) 243-3146
email@example.comMedia Contact:Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals